Literature DB >> 26586791

Impact of levosimendan and ischaemia-reperfusion injury on myocardial subsarcolemmal mitochondrial respiratory chain, mitochondrial membrane potential, Ca2+ cycling and ATP synthesis.

Stefanie Sommer1, Marcus Leistner1, Ivan Aleksic1, Christoph Schimmer1, Khaled Alhussini1, Peer Kanofsky1, Rainer G Leyh1, Sebastian-Patrick Sommer2.   

Abstract

OBJECTIVES: Levosimendan (LS) is increasingly used in case of myocardial failure after cardiac surgery. The impact of LS on myocardial mitochondrial functions, such as respiratory chain function (RCF), mitochondrial membrane potential (ΔΨm), Ca(2+) handling, mitochondrial permeability transition pore (mPTP) opening and ATP during ongoing ischaemia/reperfusion (IR) injury, is not well understood. Depending on LS, I/R injury or the combination of both, we analysed myocardial functions in a retrograde Langendorff-model followed by the analysis of subsarcolemmal mitochondrial (SSM) functions.
METHODS: Rat hearts were divided into four study groups; two were subjected to 30 min of perfusion without (control) or with the application of 1.4 µmol/20 min LS (Levo). Experiments were repeated with hearts being subjected to 40 min of normothermic stop-flow ischaemia and 30 min of reperfusion without (IR) or with LS application (Levo-IR). Systolic left ventricular pressure (LVPsys), left ventricular contractility (LVdp/dtmax) and coronary flow were determined. SSM were analysed regarding RCF, ΔΨm, ATP, and Ca(2+) retention capacity (CRC), Ca(2+)-induced swelling and Ca(2+) fluxes after (re)perfusion.
RESULTS: I/R injury suppressed LVdp/dtmax (1381 ± 927 vs 2464 ± 913 mmHg/s; P = 0.01 at 30 min (re-)perfusion time). IR revealed complex I-V state3 (19.1 ± 7.4 vs 27.6 ± 11.0 nmolO2/min; P < 0.044) and II-V state3 (20.6 ± 6.8 vs 37.3 ± 9.10 molO2/min; P < 0.0001) suppression and Levo limited I-V (14.8 ± 11.1 vs 27.6 ± 11.0 nmolO2/min; P < 0.001) and II-V (24.1 ± 6.4 vs 37.3 ± 9.10 molO2/min; P < 0.0001) function. After energizing, ΔΨm hypopolarization was observed in Levo (0.76 ± 0.04 vs 0.84 ± 0.04; P = 0.02), IR (0.75 ± 0.06 vs 0.84 ± 0.04; P = 0.007) and Levo-IR (0.75 ± 0.06 vs 0.06 ± 0.04; P = 0.01). IR (AUC: 626 vs 292; P = 0.023) and Levo-IR (AUC: 683 vs 292, P = 0.003) increased Ca(2+)-induced mPTP-opening susceptibility. CRC declined in IR (6.4 ± 2.1 vs 10.5 ± 2.6; P = 0.04) or Levo (6.5 ± 2.0 vs 10.5 ± 2.6; P = 0.023). Ca(2+) uptake was delayed in IR and Levo-IR without LS impact (P < 0.0001). Ca(2+) liberation was increased in Levo-IR. ATP synthesis was reduced in Levo (0.49 ± 0.14 vs 0.74 ± 0.14; P = 0.002) and Levo-I/R (0.34 ± 0.18 vs 0.74 ± 0.14; P < 0.002).
CONCLUSION: LS limited RCF at complex IV and V with ΔΨm hypopolarization suggesting a specific [Formula: see text]-dependent pathway. Ca(2+) redistribution from SSM by LS during I/R injury possibly prevents from Ca(2+) overload due to mPTP flickering. LS-induced mPTP flickering did not promote permanent Ca(2+)-induced mPTP opening. LS-dependent inhibition of ATP generation presumably resulted from complex IV and V limitations and lowered ΔΨm. However, a resulting impact of limited ATP synthesis on myocardial recovery remains arguable.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Ca2+; Ischaemia/reperfusion injury; Levosimendan; Mitochondria; Myocardium; ΔΨm

Mesh:

Substances:

Year:  2015        PMID: 26586791     DOI: 10.1093/ejcts/ezv397

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy.

Authors:  Juan José Jiménez-Rivera; Andrea Álvarez-Castillo; Jorge Ferrer-Rodríguez; José Luis Iribarren-Sarrías; Martín Jesús García-González; Pablo Jorge-Pérez; Juan Lacalzada-Almeida; Rosalía Pérez-Hernández; Javier Montoto-López; Rafael Martínez-Sanz
Journal:  J Cardiothorac Surg       Date:  2020-05-24       Impact factor: 1.637

2.  Levosimendan Improves Oxidative Balance in Cardiogenic Shock/Low Cardiac Output Patients.

Authors:  Elena Grossini; Serena Farruggio; Daniele Pierelli; Virginia Bolzani; Lidia Rossi; Piero Pollesello; Carolina Monaco
Journal:  J Clin Med       Date:  2020-01-30       Impact factor: 4.241

Review 3.  Regulation of Mitochondrial Quality Control by Natural Drugs in the Treatment of Cardiovascular Diseases: Potential and Advantages.

Authors:  Xing Chang; Wenjin Zhang; Zhenyu Zhao; Chunxia Ma; Tian Zhang; Qingyan Meng; Peizheng Yan; Lei Zhang; Yuping Zhao
Journal:  Front Cell Dev Biol       Date:  2020-12-23

4.  Ubiquitinated AIF is a major mediator of hypoxia-induced mitochondrial dysfunction and pulmonary artery smooth muscle cell proliferation.

Authors:  Cui Ma; Xiaoying Wang; Siyu He; Lixin Zhang; June Bai; Lihui Qu; Jing Qi; Xiaodong Zheng; Xiangrui Zhu; Jian Mei; Xiaoyu Guan; Hao Yuan; Daling Zhu
Journal:  Cell Biosci       Date:  2022-01-28       Impact factor: 7.133

Review 5.  Novel Insights Into the Role of Mitochondria-Derived Peptides in Myocardial Infarction.

Authors:  Dan Wu; Enny Kampmann; Geng Qian
Journal:  Front Physiol       Date:  2021-10-28       Impact factor: 4.755

6.  Levosimendan increases brain tissue oxygen levels after cardiopulmonary resuscitation independent of cardiac function and cerebral perfusion.

Authors:  Andreas García-Bardon; Jens Kamuf; Alexander Ziebart; Tanghua Liu; Nadia Krebs; Bastian Dünges; Robert F Kelm; Svenja Morsbach; Kristin Mohr; Axel Heimann; Erik K Hartmann; Serge C Thal
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

7.  High Pressure-Induced mtDNA Alterations in Retinal Ganglion Cells and Subsequent Apoptosis.

Authors:  Sheng-Hai Zhang; Feng-Juan Gao; Zhong-Mou Sun; Ping Xu; Jun-Yi Chen; Xing-Huai Sun; Ji-Hong Wu
Journal:  Front Cell Neurosci       Date:  2016-11-24       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.